June 14, 2011

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

.   .   

The highest risk of cytomegalovirus (CMV) disease post-transplant is in seronegative recipients who receive a kidney from a seropositive donor. In this randomized controlled trial, a vaccine resulted in production of antibodies. Among those patients subsequently transplanted, CMV viremia responded to treatment with ganciclovir more quickly in vaccinated patients.

Related Articles:

Renal Transplantation

Comments are closed.